ReviewCurrent medicinal chemistry2016
A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone.
Review in Current medicinal chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 49 citations in OpenAlex.
- Novel 4-quinolone derivative inflicted cytotoxicity via intrinsic apoptotic pathway activation on human metastatic triple-negative breast cancer cells.Bioorganic chemistry · 2025Article
- The most recent updates on the anticancer potential of fluoroquinolones: a mini review.Future medicinal chemistry · 2025Review
- Quinolin-4-ones: Methods of Synthesis and Application in Medicine.Molecules (Basel, Switzerland) · 2025Review
- Drug repurposing of fluoroquinolones as anticancer agents in 2023.RSC advances · 2024Review
- Article
- Mechanisms of the Antineoplastic Effects of New Fluoroquinolones in 2D and 3D Human Breast and Bladder Cancer Cell Lines.Cancers · 2024Article
- Change in Tissue Microbiome and Related Human Beta Defensin Levels Induced by Antibiotic Use in Bladder Carcinoma.International journal of molecular sciences · 2024Article
- Design, synthesis and in vitro anticancer activity of some new lomefloxacin derivatives.Scientific reports · 2024Article
- Quinolone Derivatives as Anticancer Agents: Importance in Medicinal Chemistry.Current topics in medicinal chemistry · 2024Review
- Design, synthesis, and biological evaluation of novel ciprofloxacin derivatives as potential anticancer agents targeting topoisomerase II enzyme.Journal of enzyme inhibition and medicinal chemistry · 2023Article
- Newly Substituted Anilino-Fluoroquinolones with Proliferation Inhibition Potential against a Panel of Cancer Cell Lines.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Kynurenine-3-monooxygenase (KMO) broadly inhibits viral infections via triggering NMDAR/Ca2+ influx and CaMKII/ IRF3-mediated IFN-β production.PLoS pathogens · 2022Article
- Common themes in antimicrobial and anticancer drug resistance.Frontiers in microbiology · 2022Review
- Nitric Oxide Photo-Donor Hybrids of Ciprofloxacin and Norfloxacin: A Shift in Activity from Antimicrobial to Anticancer Agents.Journal of medicinal chemistry · 2021Article
- A Novel Class of Functionalized Synthetic Fluoroquinolones with Dual Antiproliferative - Antimicrobial Capacities.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Tree-Based QSAR Model for Drug Repurposing in the Discovery of New Antibacterial Compounds AgainstPharmaceuticals (Basel, Switzerland) · 2020Article
- Modulating microRNA Processing: Enoxacin, the Progenitor of a New Class of Drugs.Journal of medicinal chemistry · 2020Article
- Crystal structure, Hirshfeld surface analysis and inter-action energy and DFT studies of 2-chloro-ethyl 2-oxo-1-(prop-2-yn-1-yl)-1,2-di-hydro-quinoline-4-carboxyl-ate.Acta crystallographica. Section E, Crystallographic communications · 2019Article
- HyperFoods: Machine intelligent mapping of cancer-beating molecules in foods.Scientific reports · 2019Article
- Effect of Ciprofloxacin on Susceptibility to Aortic Dissection and Rupture in Mice.JAMA surgery · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the late 1980s, reports emerged describing experimental antibacterial quinolones having significant potency against eukaryotic Type II topoisomerases (topo II) and showing cytotoxic activity against tumor cell lines. As a result, several pharmaceutical companies initiated quinolone anticancer programs to explore the potential of this class in comparison to conventional human topo II inhibiting antitumor drugs such as doxorubicin and etoposide. In this review, we present a modern re-evaluation of the anticancer potential of the quinolone class in the context of today's predominantly pathway-based (rather than cytotoxicity-based) oncology drug R&D environment. The quinolone eukaryotic SAR is comprehensively discussed, contrasted with the corresponding prokaryotic data, and merged with recent structural biology information which is now beginning to help explain the basis for that SAR. Quinolone topo II inhibitors appear to be much less susceptible to efflux-mediated resistance, a current limitation of therapy with conventional agents. Recent advances in the biological understanding of human topo II isoforms suggest that significant progress might now be made in overcoming two other treatment-limiting disadvantages of conventional topo II inhibitors, namely cardiotoxicity and drug-induced secondary leukemias. We propose that quinolone class topo II inhibitors could have a useful future therapeutic role due to the continued need for effective topo II drugs in many cancer treatment settings, and due to the recent biological and structural advances which can now provide, for the first time, specific guidance for the design of a new class of inhibitors potentially superior to existing agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.